News about GMP/cGMP


Intended Revision of mandatory USP chapter <797> “Sterile Compounding”

The Compounding Expert Committee intends a revision of the General Chapter USP <797> Pharmaceutical Compounding – Sterile Compounding. The draft version has been published for public commentation until November 30, 2018.

This is the second revision cycle. The new version contains several major changes, e.g.

  • Definition of the scope of the chapter to include sterile compounding activities and exclude administration of medication (e.g., withdrawing doses for administration).
  • Simplified compounded sterile preparation (CSP) microbial risk levels from three (low, medium, and high) to two—Category 1 CSPs and Category 2 CSPs. Category 1 and 2 CSPs are distinguished primarily by the facility in which they are made and the time period within which they must be used, i.e., the beyond-use date (BUD).
  • Addition of guidance on use and storage of opened or needle-punctured conventionally manufactured products and CSPs.
  • Addition of information on notification and recall of CSPs that have out-of-specification results.
  • Clarification of requirements for compounding allergenic extract prescription sets.
  • Removal of information related to handling of hazardous drugs and addition of references to Hazardous Drugs—Handling in Healthcare Settings 〈800〉.
  • Removal of the section on radiopharmaceuticals as CSPs and addition of a reference to Radiopharmaceuticals—Preparation, Compounding, Dispensing, and Repackaging 〈825〉. General chapter 〈825〉 is also proposed for public comment in PF 44(5).

More information can be found here.




No comment has yet been written about this news

Write your comment about this news